Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

One year of ND0612 reduced off time, increased good on time

Note: This story was updated Oct. 7, 2024, to correct references to the open-label extension study of the BounDNless trial. A year of treatment with ND0612, an investigational liquid formulation of levodopa/carbidopa continuously administered as an infusion under the skin, sustainably reduced the periods of time when motor symptoms…

Tavapadon eases motor symptoms in early Parkinson’s: Study

Treatment with tavapadon as a fixed-dose single therapy significantly improved motor function in early stage Parkinson’s disease, according to top-line data from a completed Phase 3 trial. Full results from TEMPO-1 (NCT04201093) will be presented at future medical meetings and support regulatory submissions toward the investigational therapy’s approval.

New mouse model captures disease progression, from gut to brain

A new mouse model replicates the symptoms of Parkinson’s disease and its progression in patients, beginning with diminished smell and other disease nonmotor symptoms that are early signs of the neurodegenerative disorder and often evident before problems with gait and balance arrive, scientists report. Many mouse models overexpress…

Extended-release Parkinson’s therapy Crexont available in US

Crexont, an extended-release formulation of levodopa and carbidopa, is now available in pharmacies across the U.S. for people with Parkinson’s disease. The Parkinson’s therapy, marketed by Amneal Pharmaceuticals  is designed to maintain steady levels of levodopa and carbidopa in the body, extending periods of optimal symptom management,…

Healthcare costs factor high in Parkinson’s economic burden

Healthcare services contribute to nearly half the total expenses associated with Parkinson’s disease, but the loss of productivity and the financial burden on patients and their families also have a substantial impact, a study shows. The study estimated the average annual cost per patient with Parkinson’s disease is about…

Electroacupuncture reduced cellular signs of Parkinson’s in mouse model

Electroacupuncture reduced cellular hallmarks of Parkinson’s disease, including alpha-synuclein accumulation and nerve cell degeneration, in a mouse model of the disease. That’s according to the findings from a study that also found the treatment, a type of acupuncture where small needles inserted at specific points in the body are…

New panel of cell-based tests may help screen potential treatments

Ncardia has launched a panel of ready-to-use cell-based assays to simplify the screening and selection of treatment candidates for neurodegenerative diseases, including Parkinson’s disease. The assays are based on human-derived induced pluripotent stem cells (iPSCs), a type of stem cell that can generate nearly all types of cells.

New biosensor can detect dopamine in unprocessed blood samples

A newly developed biosensor that can rapidly detect and quantify levels of dopamine — a chemical messenger nerve cells use to communicate — may serve as a low-cost and efficient tool to diagnose and monitor people with Parkinson’s disease or other conditions marked by abnormal dopamine levels. Developed by…

Mood, cognition issues tied to deficit recognizing, describing emotions

Having difficulty recognizing and describing emotions may be associated with cognitive issues and with mood disorders such as depression, apathy, and impulse control problems in people with Parkinson’s disease, a review study suggests. As a result, the condition, called alexithymia, or emotional blindness, may reduce patients’ health-related quality of…